Alamar Biosciences (NASDAQ:ALMR) Stock Price Target Raised at TD Cowen

Alamar Biosciences (NASDAQ:ALMR) had its price target lifted by TD Cowen from $34.00 to $36.00 in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other analysts have also recently issued reports about the stock. JPMorgan Chase & Co. upped their price target on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Stifel Nicolaus boosted their target price on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings downgraded shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Alamar Biosciences presently has a consensus rating of “Hold” and an average price target of $33.00.

Alamar Biosciences Price Performance

Shares of ALMR opened at $27.39 on Wednesday. Alamar Biosciences has a one year low of $18.84 and a one year high of $39.61. The company has a 50-day simple moving average of $30.38. The company has a quick ratio of 10.23, a current ratio of 11.85 and a debt-to-equity ratio of 0.03.

Alamar Biosciences (NASDAQ:ALMR) last released its earnings results on Wednesday, November 4th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.03. The business had revenue of $33.55 million for the quarter. On average, equities research analysts anticipate that Alamar Biosciences will post -1.22 earnings per share for the current year.

Insider Buying and Selling at Alamar Biosciences

In other news, major shareholder Corporate Gp Vi Ltd. Qiming sold 43,930 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $29.84, for a total transaction of $1,310,871.20. Following the completion of the transaction, the insider directly owned 160,913 shares in the company, valued at approximately $4,801,643.92. The trade was a 21.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 1,387,636 shares of company stock valued at $41,234,931.

Hedge Funds Weigh In On Alamar Biosciences

Large investors have recently bought and sold shares of the stock. Braidwell LP bought a new stake in shares of Alamar Biosciences during the 2nd quarter worth about $29,365,000. Wellington Management Group LLP bought a new position in shares of Alamar Biosciences in the second quarter valued at approximately $12,407,000. State Street Corp acquired a new position in shares of Alamar Biosciences during the second quarter valued at approximately $3,930,000. Sumitomo Mitsui Trust Group Inc. lifted its position in Alamar Biosciences by 18.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock worth $2,280,000 after purchasing an additional 10,461 shares during the period. Finally, Squarepoint Ops LLC bought a new position in Alamar Biosciences during the 2nd quarter valued at $283,000.

Alamar Biosciences News Roundup

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported third-quarter revenue of $33.55 million, up 68% year over year, and a loss of $0.19 per share—narrower than analysts’ expected $0.22 loss. It also raised 2026 revenue guidance to $121 million–$123 million. Alamar Q3 results and guidance
• Positive Sentiment: TD Cowen raised its price target to $36 from $34 and maintained a Buy rating; BofA Securities lifted its target to $35 from $31. Higher targets signal continued analyst confidence in the shares. BofA Securities price target update
• Positive Sentiment: Alamar and GSK will use Alamar’s NULISA platform in a large-scale proteomics study spanning several disease areas. The collaboration could raise the platform’s profile, although no financial terms were announced. GSK collaboration announcement
• Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming has been selling shares, including 43,930 shares on November 2 and 143,706 on October 30. The repeated sales may add pressure to the stock, though the filings do not give a reason for the transactions. SEC filing on shareholder sales

Alamar Biosciences Company Profile

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.